Search Within

Zaki Molvi

Formats
  1. Journal Article (5)
  2. Meeting Abstract (3)
  3. Review (2)
  4. Editorial (1)
Groups
  1. Department of Medicine (11)
  2. GSK Faculty (11)
  3. MSK Grad Students (11)
  4. Sloan Kettering Institute Postdocs (11)
  5. Tow Center for Developmental Oncology (TCDO) (11)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (10)

More Groups

People
  1. Richard O'Reilly (7)
  2. David Scheinberg (5)
  3. Tao Dao (4)
  4. Elisabeth Nyakatura (3)
  5. Paul Balderes (3)
  6. Abdul Khan (2)

More People

Years
  1. 2024 (1)
  2. 2023 (4)
  3. 2022 (4)
  4. 2021 (2)
Publications
  1. Journal for ImmunoTherapy of Cancer (2)
  2. Cancer Treatment and Research (1)
  3. European Journal of Nuclear Medicine and Molecular Imaging (1)
  4. Frontiers in Immunology (1)
  5. Haematologica (1)
  6. Immunological Reviews (1)

More Publications

Publishers
  1. Biomed Central Ltd (2)
  2. Springer (2)
  3. Amer Soc Clinical Investigation Inc (1)
  4. American Association for the Advancement of Science (1)
  5. Elsevier Science Inc. (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • (89)Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia
    Journal Article

    Herrero Alvarez, N.; Molvi, Z.; Lupo, K.; Urraca, J.; Balderes, P.; Nyakatura, E. K.; Khan, A. G.; Viray, T.; Lewis, J. S.; O’Reilly, R. J.
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Challenges and solutions for therapeutic TCR-based agents
    Review

    Malviya, M.; Aretz, Z. E. H.; Molvi, Z.; Lee, J.; Pierre, S.; Wallisch, P.; Dao, T.; Scheinberg, D. A.
    Immunological Reviews (2023)

    Fulltext@MSK | Save
  • The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
    Journal Article

    Molvi, Z.; Klatt, M. G.; Dao, T.; Urraca, J.; Scheinberg, D. A.; O'Reilly, R. J.
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Cytomegalovirus-specific T cells following haploidentical transplants: Reshaping a repertoire by half
    Editorial

    O'Reilly, R. J.; Molvi, Z.
    Haematologica (2023)

    Fulltext@MSK | Save
  • (89)Z-immuno-PET guided preclinical development of targeted therapies: Demonstrating utility by evaluating fusion proteins in vivo
    Meeting Abstract

    Herrero Alvarez, N.; Lewis, J.; Molvi, Z.; O'Reilly, R.; Nyakatura, E.; Balderes, P.; Viray, T.
    Nuclear Medicine and Biology (2022)

    Fulltext@MSK | Save
  • Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
    Journal Article

    Gigoux, M.; Holmström, M. O.; Zappasodi, R.; Park, J. J.; Pourpe, S.; Bozkus, C. C.; Mangarin, L. M. B.; Redmond, D.; Verma, S.; Schad, S.; more...
    Science Translational Medicine (2022)

    Fulltext@MSK | Save
  • Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer
    Journal Article

    Molvi, Z.; O’Reilly, R. J.
    Cancer Treatment and Research (2022)

    Fulltext@MSK | Save
  • A TCR mimic monoclonal antibody reactive with the "public" phosphoneoantigen pIRS2/HLA-A*02:01 complex
    Journal Article

    Dao, T.; Mun, S. S.; Molvi, Z.; Korontsvit, T.; Klatt, M. G.; Khan, A. G.; Nyakatura, E. K.; Pohl, M. A.; White, T. E.; Balderes, P. J.; more...
    JCI Insight (2022)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; George, M.; Venkatesh, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save